Apricus Bio VP: Drug Delivery Space Is Evolving During Personalized Medicine Surge
Apricus Bio VP Edward Cox discusses the future of drug delivery technology in the rapidly expanding world of personalized medicine.
Featured Articles
New York Biotechnology Association Gears Up for its 21st Annual Meeting
New York Biotechnology Association (NYBA) will develop its Emerging Companies Showcase at the NYBA 21st Annual Meeting, May 2 in New York City at the Marriott Marquis Hotel.
Dr. Shi of EdgeTech Law: Genome Sequencing Could Soon Enter Mainstream
In Part III of our interview with Dr. Qin Shi of Edgetech Law we visit the concept of human genome sequencing as a mainstream commodity.
NeuroMetrix to Support Study at the Joslin Diabetes Center
NeuroMetrix is investigating the impact of intensive Diabetes management on Diabetic Peripheral Neuropathy
This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Dr. Shi of EdgeTech Law: Emerging Opportunities in Life Sciences, Abroad
In Part II of our special interview series, Dr. Qin Shi of Edgetech Law discusses the emerging areas of significant unmet need in life science, and what investment opportunities may arise.
Dr. Shi of EdgeTech Law: Despite Mayo Clinic v. Prometheus “Setback,” Opportunities in Life Sciences Remain
OneMedPlace is pleased to announce a special interview series exploring current issues facing the diagnostics sector and life sciences.
NeuroMetrix Files 510(k) for SENSUS(TM) Pain Therapy Device
NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes has filed a 510(k), with the FDA for its SENSUS Pain Therapy device.
Complete Genomics Well Positioned to Move from Research to Clinical in Genome Sequencing
OneMedRadio recently conducted an interview with Dr. Clifford A. Reid, the company’s President and Chief Executive Officer.
AVI Biopharma’s Chief Science Officer To Resign
Drug developer AVI Biopharma Inc. said Thursday that Chief Scientific Officer Peter Linsley will resign from the company.